Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Category Structured summary of systematic reviews
JournalDatabase of Abstracts of Reviews of Effects (DARE)
Year 2009
Loading references information

CRD SUMMARY:

This review evaluated the effectiveness of cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs (NSAIDS) for osteoarthritis (OA) and rheumatoid arthritis (RA) patients. The authors concluded that COX-2 selective NSAIDs were similar to non-selective NSAIDs for the symptomatic relief of these conditions and provided superior GI tolerability. This was a well-conducted review and the authors' conclusions were likely to be reliable.
Epistemonikos ID: 33cb25b938715a0fa21e741ce2048effd7bb3e84
First added on: Jun 06, 2012